RHHBY - Mirati stock climbs 10% ahead of data presentation FDA meeting on rival drug
2023-09-28 16:18:43 ET
More on Mirati Therapeutics
- Mirati: Expansion Of Adagrasib With sNDA And Combination Studies
- Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript
- Mirati CFO leaving company in wake of CEO departure
- Citi upgrades Mirati to buy; cites valuation, leadership change
For further details see:
Mirati stock climbs 10% ahead of data presentation, FDA meeting on rival drug